

Special Issue

Immune Responses to COVID-19 Vaccines

Message from the Guest Editor

Special Issue includes but is not restricted to the following:

- Use, efficacy, and safety of COVID-19 vaccines in frail persons such as, but not limited to, patients with cardiopulmonary chronic diseases, COPD, Diabetes, chronic renal failure, renal transplant carriers, and oncological/onco-hematological patients; in extreme ages (elderly/newborn), in pregnancy, in patients with chronic viral infections (HIV, HBV, or HCV), primary or secondary immune depression, or suffering for immune, allergic, or autoimmune diseases, either in treatment with immune modifying drugs or not
- Impact of COVID-19 vaccines in hospitalized/institutionalized persons and personnel and in special communities
- Off label use of COVID-19 vaccines: heterologous or mixed primer-booster schedules, extended prime to boost interval
- Interaction between COVID-19 vaccines and other vaccinations in newborns, in frail newborns (to an HIV/HBV/HCV-positive mother), in elderly, in multiple exposed frail patients
- Use and development of COVID-19 vaccines in medium-low-income countries or communities
- Next generation, new formulation, and new conception of COVID-19 vaccines.

Guest Editor

Dr. Federico De Marco

Department of RDAT, the Regina Elena National Cancer Institute
IRCCS, Via Elio Chianesi 53, 00144 Rome, Italy

Deadline for manuscript submissions

closed (31 January 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/112229

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).